. 2016 Sep 1;7(1):126. doi: 10.1186/s13287-016-0386-0

Table 2.

Effect of different types of stem cells on renal tissue oxidative stress parameters (n = 20 and n = 5 for day subgroups, mean ± SD)

	Group I	Group II	Group III	Group IV	Group V	Group VI
	negative control	cisplatin ‘CDDP’-treated	cisplatin + rBMSCs-treated	cisplatin + hADSCs-treated	cisplatin + hAFSCs-treated	cisplatin + DMEM culture media-treated
MDA (nmol/gm tissue)
Day 4	14.6 ± 1.61	66.5 ± 2.83^a	34.7 ± 4.95^ab	37.0 ± 3.75^ab	34.7 ± 6.72^ab	66.6 ± 2.86^acde
Day 7	14.9 ± 1.50	64.9 ± 3.93^a	24.5 ± 4.98^ab	28.0 ± 2.58^ab	26.1 ± 2.13^ab	66.9 ± 2.29^acde
Day 11	15.4 ± 1.63	35.5 ± 3.33^a	18.4 ± 0.93^b	18.3 ± 2.20^b	17.8 ± 1.78^b	34.8 ± 2.84^acde
Day 30	15.1 ± 1.62	30.1 ± 4.61^a	16.2 ± 0.87^b	18.7 ± 2.32^b	17.6 ± 2.29^b	28.1 ± 1.58^acde
GSH (mmol/gm tissue)
Day 4	5.40 ± 0.25	0.26 ± 0.03^a	0.78 ± 0.04^ab	0.81 ± 0.11^ab	0.76 ± 0.02^ab	0.26 ± 0.02^acde
Day 7	5.44 ± 0.23	0.54 ± 0.03^a	2.65 ± 0.15^ab	2.72 ± 0.17^ab	2.64 ± 0.36^ab	0.52 ± 0.03^acde
Day 11	5.55 ± 0.17	1.49 ± 0.33^a	3.36 ± 0.14^ab	3.68 ± 0.13^ab	3.55 ± 0.15^ab	1.32 ± 0.30^acde
Day 30	5.32 ± 0.31	1.92 ± 0.03^a	5.05 ± 0.12^b	4.29 ± 0.18^abc	3.98 ± 0.43^abc	1.91 ± 0.05^acde
SOD (U/g of tissue)
Day 4	20.36 ± 1.70	2.98 ± 0.19^a	7.64 ± 0.37^ab	6.87 ± 0.39^ab	6.93 ± 0.42^ab	2.94 ± 0.23^acde
Day 7	19.92 ± 1.39	6.24 ± 0.42^a	10.85 ± 0.38^ab	10.31 ± 0.36^ab	10.69 ± 0.33^ab	6.22 ± 0.45^acde
Day 11	19.88 ± 1.40	9.98 ± 0.32^a	15.46 ± 0.32^ab	15.80 ± 0.25^ab	15.73 ± 0.29^ab	10.0 ± 0.25^acde
Day 30	20.22 ± 1.70	15.3 ± 0.36^a	18.26 ± 0.17^ab	18.62 ± 0.38^ab	18.74 ± 0.15^b	15.6 ± 0.49^acde

Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Bonferroni post hoc for multiple comparisons

rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium, MDA malondialdehyde, GSH reduced glutathione, SOD superoxide dismutase

^aSignificant difference vs. negative control group ^bSignificant difference vs. cisplatin-treated group ^cSignificant difference vs. cisplatin + rBMSCs-treated group ^dSignificant difference vs. cisplatin + hADSCs-treated group ^eSignificant difference vs. cisplatin + hAFSCs-treated group